| Literature DB >> 25887888 |
Raquel A Giovelli1,2, Maria C S Santos3,4, Érica V Serrano5, Valéria Valim6,7.
Abstract
BACKGROUND: Labial salivary gland biopsy (LSGB) is the most important diagnostic tool for the diagnosis of Sjögren's syndrome (SS), but its diagnostic value is rarely studied. This study assessed the sensibility and specificity of LSGB, and the clinical profiles of patients who were referred for biopsy.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25887888 PMCID: PMC4332430 DOI: 10.1186/s12891-015-0482-9
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Demographic and clinical characteristics of the suspected cases referred for labial salivary gland biopsy
|
|
|
|---|---|
| Age (years) | 47.7 ± 12.5 |
| Gender (Women) | 188 (87%) |
| Dryness symptoms (only) | 111 (51.4%) |
| Dryness and systemic symptoms | 92 (42.6%) |
| Systemic symptoms (only) | 12 (5.55%) |
| Virus C Hepatitis | 1 (0.45%) |
| Unstimulated salivary flow (<0.1 ml/min) | 119 (55.09%) |
| Schirmer test I (≤5 mm) | 103 (47.68%) |
| Anti-SSA and/or anti-SSB | 36 (16.66%) |
| ANA | 100 (46.29%) |
| Rheumatoid Factor (latex) | 40 (18.51%) |
| Focal Sialoadenitis (focus score ≥ 1) | 79 (36.57%) |
ANA = antinuclear antibodies.
Figure 1Flow chart study. pSS: primary Sjögren’s syndrome according to AECG, sSS: secondary Sjögren’s syndrome according to AECG, 8 SLE: Systemic Lupus Erythematosus, 6 RA: Rheumatoid Arthritis, 3 Overlap (SSc: Systemic Sclerosis, APS: Antiphospholid Syndrome, SS: Sjögren’s syndrome).
Figure 2Diagnostic flow of suspected patients of Sjögren’s syndrome. USF: unstimulated salivary flow; ST: Schirmer test; anti-SSA/SSB +: anti-SSA and/or anti-SSB positive; anti-SSA/SSB -: anti-SSA and/or anti-SSB. negative; Biopsy +: score focus ≥ 1; Biopsy -: focus score < 1; no SS: no Sjögren’s. syndrome; pSS: primary Sjögren’s syndrome according to the American European. Consensus Group 2002.
Clinical characteristics of patients with primary Sjögren’s syndrome and nonspecific dryness syndrome
|
|
|
| |
|---|---|---|---|
| Age (years) | 49.6 ± 12 | 45.8 ± 12.9 |
|
| Gender (Women) | 65 (98.5%) | 123 (94.6%) | 0.36 |
| Oral symptoms | 60 (90.9%) | 95 (85.6%) | 0.42 |
| Ocular symptoms | 61 (92.4%) | 90 (81.1%) | 0.07 |
| Salivary flow (<0.1 ml/min) | 53 (80.3%) | 51 (46.4%) |
|
| Schirmer (≤5 mm) | 42 (70.0%) | 50 (56.2%) | 0.13 |
| Focal Sialoadenitis (focus score ≥ 1) | 59 (89.4%) | 7 (5.4%) |
|
| Anti-SSA and/or anti-SSB | 21 (32.3%) | 6 (6.2%) |
|
| Rheumatoid Factor (látex) | 14 (25.9%) | 22 (21.0%) | 0.62 |
| ANA | 39 (66.1%) | 44 (40.0%) |
|
| Fibromyalgia | 41 (63%) | 57 (43.6%) |
|
| Hypertension | 26 (39.4%) | 38 (29.2%) | 0.20 |
| Dyslipidemia | 10 (15.2%) | 12 (9.2%) | 0.31 |
| Diabetes Mellitus | 4 (6.1%) | 13 (10.0%) | 0.52 |
| Depression | 8 (12.1%) | 12 (9.2%) | 0.70 |
| Hyperthyroidism, Graves Disease | 8 (12.1%) | 9 (6.9%) | 0.34 |
| Osteoporosis/Osteopenia | 8 (12.1%) | 9 (6.9%) | 0.34 |
| Osteoarthritis | 20 (30.3%) | 28 (21.5%) | 0.24 |
| Neoplasia | 5 (7.6%) | 2 (1.5%) | 0.08 |
*Chi-square Test.